| abstract |
The present invention relates to compounds of formula (I), in which R represents a hydrogen atom or a radical -COOH, -alk-COOH, -PO3H2, -CH2-PO3H2, -CH = CH-COOH or phenyl substituted by a carboxy radical, R1 represents a radical -alk-CN, -alk-COOH, -alk-Het, -alk-PO3H2 or -alk-CO-NH-SO2R2, R2 represents an alkyl or phenyl radical, alk represents an alkyl radical, Het represents a saturated or unsaturated mono or polycyclic heterocycle containing 1 with 9 carbon atoms and one or more heteroatoms chosen from O, S, N, the heterocyle being optionally substituted by one or more radicals alkyl, phenyl or phenylalkyl, it being understood that when R represents a hydrogen atom or a radical -COOH or -PO3H2, R1 cannot represent -alk-COOH, their isomers, racemates, enantiomers and diastereoisomers, their salts, their preparation, their intermediates and the drugs containing them. The compounds of formula (I) have pharmacological properties interesting. These compounds are acid receptor antagonists .alpha.-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), also known under the name of quisqualate receiver. Furthermore, the compounds of formula (I) are non-competitive N-methyl-D-aspartate receptor antagonists (NMDA) and, more particularly, they are ligands for the sites NMDA receptor glycine modulators. |